Results 51 to 60 of about 240,836 (199)

Andexanet Alfa in Urgent Cardiac Surgery: A Case Report of Edoxaban Reversal for Acute Hemopericardium. [PDF]

Am J Case Rep
Patient: Female, 71-year-old Final Diagnosis: Cardiac shock • pericardtamponade • sever mitral valve regurgitation Symptoms: Agitation • dyspnea Clinical Procedure: — Specialty: Anesthesiology • Cardiac Surgery • Cardiology • Critical Care Medicine ...
Al Mawed M, Warkentin H, Brockmeier JP, Schramm R, Gummert J, von Dossow V, Gielen S.   +6 more
europepmc   +2 more sources

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2022
Introduction Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity.
Joseph Lewis BA, Omer Iqbal MD, Walter Jeske PhD, Debra Hoppensteadt PhD, Fakiha Siddiqui BDS, Jawed Fareed PhD   +5 more
doaj   +1 more source

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Critical Care, 2022
Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding.
Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman   +6 more
doaj   +1 more source

Andexanet alfa in patients with factor Xa inhibitor-associated intracranial hemorrhage: The prospective observational multicenter ASTRO-DE study. [PDF]

Int J Stroke
Background: Hematoma expansion after intracranial hemorrhage (ICH) in anticoagulated patients significantly influences clinical outcomes and mortality, emphasizing the need for effective reversal agents.
Diener HC, Kuklik N, Hüsing A, Alonso A, Nabavi DG, Poli S, Gabriel MM, Maier IL, Grans J.   +8 more
europepmc   +2 more sources

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban

, 2022
Background Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban.
Middeldorp, S., Milling, T.J., Jr., Yue, P., Conley, P., Crowther, M., Benz, A.P., Lu, G., Connolly, S.J., Eikelboom, J.W., Xu, L., Lu, Genmin, Connolly, Stuart J., Patrick Yue, Crowther, Mark, Conley, Pamela, Lizhen Xu, Mark Crowther, Yue, Patrick, Genmin Lu, Stuart J. Connolly, Middeldorp, Saskia, Saskia Middeldorp, Benz, Alexander P., Truman J. Milling, Xu, Lizhen, John W. Eikelboom, null null, Milling, Truman J., Alexander P. Benz, Pamela Conley, Eikelboom, John W.   +30 more
core   +1 more source

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Clinical and Applied Thrombosis/Hemostasis, 2019
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment.
Victoria M. Stevens PharmD, Toby Trujillo PharmD, FCCP, FAHA, BCPS-AQ Cardiology, Scott W. Mueller PharmD, BCCCP, FCCM, Robert MacLaren PharmD, FCCM, FCCP, Paul M. Reynolds PharmD, BCCCP, Tyree H. Kiser PharmD, FCCM, FCCP, BCPS   +5 more
doaj   +1 more source

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists

Clinical and Applied Thrombosis/Hemostasis, 2022
Direct oral factor Xa inhibitors (DXIs) are approved for use in adult patients with non-valvular heart disease for stroke prevention, and the treatment/prevention of venous thromboembolism (VTE).
Vilmarie Rodriguez MD, MS, Joseph Stanek MS, Bryce A. Kerlin MD, Amy L. Dunn MD   +3 more
doaj   +1 more source

Andexanet alfa is an effective reversal agent for factor Xa inhibitors in patients that develop intracranial hemorrhage [PDF]

, 2019
A critical appraisal and clinical application of Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-1141.
Friedli, Joseph
core   +1 more source

Andexanet Alfa-Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives. [PDF]

Arterioscler Thromb Vasc Biol
Chabata CV, Yu H, Ke L, Frederiksen JW, Patel PA, Sullenger BA, Thalji NK.   +6 more
europepmc   +2 more sources

Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans.

American Journal of Emergency Medicine
BACKGROUND AND OBJECTIVES Two hemostatic agents are commonly used to reverse factor Xa (fXa) inhibitor-related intracranial hemorrhage (ICH): andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC).
M. Rech, E. Budde, Charlesnika T Evans, D. Finch, Ying-Lin Xia, Zhi-Ping Huo, Jin H. Han   +6 more
semanticscholar   +1 more source